Australian industry tightens code of conduct but more sunshine to come?
This article was originally published in Scrip
Following 18 months of review and consultations, Medicines Australia has revised its code of conduct for member companies, which from next year will be required to make new disclosures about payments to medical professionals.
You may also be interested in...
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.